Endacea Home Page

Description: Endacea is a development stage biopharmaceutical company with a proprietary A1 adenosine receptor based technology platform for the treatment of asthma, ischemia-reperfusion organ injury, and Gram-negative septicemia (endotoxemia), as well as an assay for endotoxin.

Keywords: adenosine, A1AR, inflammation, anti-inflammatory, endotoxin, endotoxemia, septicemia, sepsis, asthma, ischemia, reperfusion, ischemia-reperfusion, P2x, purinoceptor, Gram-negative, fibrosis, sclerosis, myocardial, infarction, purine, COPD, autoimmune

Tags: endacea, home, page, contact, science, company, careers, sepsis, ischemia, reperfusion, renal, impairment, adenosine, asthma, drug, including, gram, endotoxemia, negative, endotoxin, septicemia, anti, inflammation, receptor, biopharmaceutical, proprietary, acute, candidate, antagonists, biomarker, patents, use, developing, methods, antagonist, fibrosis, sclerosis, purinoceptor, inflammatory, copd,

Endacea.net

Content Revalency: Title: 66.67%   Description: 21.21%   Keywords: 20.00%  |  Document size: 9,039 bytes
More info: Whois - Trace Route - RBL Check